A director exercised options at $1.60 and sold 3,500 Oric Pharmaceuticals (ORIC) shares.
Richard A. Heyman, a director at Oric Pharmaceuticals (ORIC), exercised 3,500 options at an exercise price of $1.60 per share on October 1, 2026. Concurrently, Heyman sold 3,500 directly held shares, and RAHD Capital, LLC, over which he has voting and investment power, sold an additional 3,200 shares. Both sales were executed under a Rule 10b5-1 trading plan at a reported price of $12.9141 per share.
Six new hires received options to buy shares and stock awards from ORIC Pharmaceuticals
ORIC Pharmaceuticals granted equity awards to six new non-executive employees on October 1, 2026, as an inducement for employment. The awards include 161,550 non-qualified stock options and 26,850 restricted stock units, approved under Nasdaq Listing Rule 5635(c)(4). These grants are subject to continued employment and vest over different schedules, with options vesting 25% after one year and RSUs vesting one-third annually over three years.
Form 144 Oric Pharmaceuticals For: 1 October By Investing.com
This article from Investing.com is a regulatory filing notification, specifically a Form 144 for Oric Pharmaceuticals, dated October 1. It provides no further details beyond the filing's existence and the company's stock symbol. The article also includes various market data and related news.
Form 144 Oric Pharmaceuticals For: 1 October By Investing.com
This article reports on a Form 144 filing for Oric Pharmaceuticals on October 1st. It also notes a -7.05% change in ORIC's stock. The content includes general financial market data and news headlines, but the primary focus is on the Oric Pharmaceuticals filing.
Price to earnings ratio of Oric Pharmaceuticals, Inc. – HAN:4TZ
This article provides financial information for Oric Pharmaceuticals, Inc. (HAN:4TZ) listed on the Hannover Stock Exchange. It specifically focuses on the company's price-to-earnings ratio and indicates that the market is currently closed with no trades. The content is primarily a data placeholder within a financial platform.
A director proposes selling 8,100 shares of Oric Pharmaceuticals (ORIC).
Oric Pharmaceuticals director Richard A. Heyman has filed a Form 144 notice proposing to sell 8,100 common shares with an aggregate market value of $109,107. Some of these sales will result from cashless option exercises occurring within three months of October 1, 2026. The filing also details prior sales by Heyman and RAHD Capital, LLC in the past three months.
A proposed sale covers 7,600 Oric Pharmaceuticals (ORIC) shares held by RAHD Capital.
RAHD Capital, LLC, managed by director Richard A. Heyman, has filed a notice for the proposed sale of 7,600 common shares of Oric Pharmaceuticals (ORIC) valued at approximately $102,372. The shares were originally acquired in a private investment on July 31, 2015. J.P. Morgan Securities LLC is listed as the broker for the transaction, which has an approximate sale date of October 1, 2026.
Diluted shares outstanding of Oric Pharmaceuticals, Inc. – HAN:4TZ
This article provides financial data on the diluted shares outstanding of Oric Pharmaceuticals, Inc. (HAN:4TZ) traded on the Hannover Stock Exchange. It focuses solely on this specific financial metric, indicating the value and percentage change over a given period.
After a $4.36 option exercise, Oric Pharmaceuticals (ORIC) CFO sells 13,400 shares.
Oric Pharmaceuticals' CFO, Dominic Piscitelli, exercised options to acquire 13,400 common shares at $4.36 each on September 28, 2026. Immediately after, he sold all 13,400 shares at a weighted average price of $13.5267 per share, generating an approximate pre-tax spread of $123,000. This transaction was conducted under a Rule 10b5-1 trading plan adopted in May 2026, and his remaining option position after the exercise was 78,500 options.
ORIC Pharmaceuticals (ORIC) CFO Dominic Piscitelli Sells 13,400 Shares
ORIC Pharmaceuticals CFO Dominic Piscitelli recently sold 13,400 shares, reducing his direct holdings to 69,828 shares. This sale is part of a broader pattern of insider selling at ORIC, with 13 insider sells and zero insider buys over the past year. The company is a clinical-stage biopharmaceutical firm focused on oncology, with valuation primarily driven by its pipeline potential rather than current revenue.
Taxes of Oric Pharmaceuticals, Inc. – HAN:4TZ
This article displays the title "Taxes of Oric Pharmaceuticals, Inc. – HAN:4TZ" from TradingView, specifically from the Hannover Stock Exchange. The page appears to be a financial overview for Oric Pharmaceuticals, Inc. (4TZ) but provides no detailed tax information or financial figures within the visible content.
CapEx per share of Oric Pharmaceuticals, Inc. – HAN:4TZ
This article provides a brief financial overview of Oric Pharmaceuticals, Inc. (HAN:4TZ), specifically focusing on its Capital Expenditure (CapEx) per share. It appears to be a financial data point from TradingView, indicating a value, change, and percentage change for this metric.
Oric Pharmaceuticals (NASDAQ:ORIC) CFO Sells $181,302.00 in Stock
Oric Pharmaceuticals (NASDAQ:ORIC) CFO Dominic Piscitelli sold 13,400 shares of the company's stock for approximately $181,302, reducing his direct holdings by 16.1% to 69,828 shares. This sale was conducted under a pre-arranged Rule 10b5-1 trading plan and follows other recent sales by Piscitelli. Despite the insider selling and a slight earnings miss, analysts maintain a "Moderate Buy" rating for Oric Pharmaceuticals with a consensus price target of $20.18, and institutional investors own a significant 95.05% of the company's stock.
Oric Pharma CFO sells $181k in shares
Oric Pharmaceuticals CFO, Dominic Piscitelli, sold 13,400 shares for approximately $181,257 after exercising stock options. This transaction follows a significant 63% year-to-date surge in ORIC shares, with analysts maintaining a bullish outlook and price targets up to $27, even as InvestingPro suggests the stock is trading above its Fair Value. The company is also advancing a global Phase 3 trial for prostate cancer, which has garnered positive analyst attention.
Form 4 Oric Pharmaceuticals Inc For: 29 September By Investing.com
This article from Investing.com reports on a Form 4 filing for Oric Pharmaceuticals Inc., pertaining to transactions that occurred on September 29. The brief piece includes the company's stock symbol ORIC and its current performance (-2.48%). It serves as a direct announcement of the filing without further analysis.
Oric Pharmaceuticals, Inc. (NASDAQ:ORIC) Stock Has Average Target Price of $20.18
Oric Pharmaceuticals (NASDAQ:ORIC) has an average target price of $20.18, with analysts maintaining a "Moderate Buy" consensus. The stock opened at $13.27, implying potential upside, despite the company reporting a quarterly loss of $0.38 per share, which was slightly worse than expected. Institutional investors hold a significant 95.05% stake in the company, though CFO Dominic Piscitelli recently sold a substantial number of shares.
1,078,055 Shares of Oric Pharmaceuticals, Inc. $ORIC Purchased by Bank of America Corp DE
Bank of America Corp DE recently acquired 1,078,055 shares of Oric Pharmaceuticals (NASDAQ:ORIC), valued at approximately $11.7 million, representing about 1.04% of the company. Institutional investors now own 95.05% of ORIC, and analysts maintain a "Moderate Buy" consensus with an average price target of $20.18. The company recently reported a quarterly loss of $0.38 per share, missing estimates, and its CFO sold 77,000 shares under a pre-arranged trading plan.
Form 4 Oric Pharmaceuticals Inc For: 25 September By Investing.com
This article reports on the filing of Form 4 by Oric Pharmaceuticals Inc. for transactions that occurred on September 25. Form 4 is a document that must be filed with the U.S. Securities and Exchange Commission (SEC) whenever there is a change in the beneficial ownership of a company's securities by insiders. The article includes the stock symbol ORIC and notes a 0.84% increase.
Form 4 Oric Pharmaceuticals Inc For: 25 September
This article announces the filing of a Form 4 for Oric Pharmaceuticals Inc. on September 25th. Form 4s report changes in beneficial ownership of company stock by insiders. The article provides only this headline information without further details on the transaction itself.
A finance chief exercised 600 options and sold 600 shares at Oric Pharmaceuticals (ORIC).
Oric Pharmaceuticals' CFO, Dominic Piscitelli, exercised 600 options at $4.36 per share and simultaneously sold 600 common shares on September 24, 2026. These transactions, consisting of two separate sales at $13.50 and $13.505 per share, were conducted under a pre-arranged Rule 10b5-1 trading plan established on May 26, 2026. Following these transactions, Piscitelli holds 91,900 stock options and 69,828 common shares.
Oric Pharmaceuticals CFO Dominic Piscitelli sells $8,102 in shares
Oric Pharmaceuticals CFO Dominic Piscitelli sold 600 shares of the company's common stock for $8,102 on September 24, 2026, under a Rule 10b5-1 trading plan. Concurrently, he acquired 600 shares by exercising stock options valued at $2,616. These transactions leave him with 69,828 shares and 91,900 stock options, as ORIC shares trade near $13.16, up 61% year-to-date, despite being considered overvalued by InvestingPro.
ORIC Pharmaceuticals stock trades 10.7 percent below its 52-week high
ORIC Pharmaceuticals stock is trading 10.7 percent below its 52-week high at USD 13.33. The company is advancing two late-stage oncology programs, including the Phase 3 Himalayas-1 study for prostate cancer, with top-line data expected in early 2028. Despite a Q2 loss of USD 0.38 per share, ORIC holds significant cash reserves to fund its clinical trials.
Oric Pharmaceuticals (NASDAQ:ORIC) Shares Gap Up - Still a Buy?
Oric Pharmaceuticals (NASDAQ:ORIC) shares gapped up before market open but traded down to $13.3950. The company, a clinical-stage cancer biopharmaceutical firm, reported a quarterly loss of $0.38 per share and has a "Moderate Buy" consensus rating from analysts with an average price target of $20.18. Despite a CFO selling over 77,000 shares, institutional investors own 95.05% of the stock.
BTIG initiates ORIC Pharmaceuticals stock coverage with buy rating
BTIG has initiated coverage on ORIC Pharmaceuticals (NASDAQ:ORIC) with a Buy rating and a price target of $26.00, suggesting a potential upside of 93% from its current trading price of $13.50. The firm believes ORIC stock is undervalued ahead of significant internal and external data catalysts, particularly for its lead programs rinzimetostat and enozertinib. The company also maintains a strong financial position with cash reserves extending into the second half of 2028.
BTIG initiates coverage of ORIC Pharmaceuticals with Buy rating, $26 price target
BTIG has initiated coverage on ORIC Pharmaceuticals with a "Buy" rating and a $26 price target, implying a 92.6% upside from the previous close. The positive outlook is based on ORIC's strong pipeline of innovative therapies, particularly rinzimetostat for prostate cancer, and the significant market potential of its treatments targeting large, underserved patient populations.
ORIC - Late-Stage Cancer Trials And Strong Cash Runway Will Support Long-Term Upside Potential
ORIC Pharmaceuticals is positioned for long-term growth with its late-stage cancer trials for rinzimetostat and enozertinib, targeting multi-billion dollar markets in metastatic prostate and precision lung cancer. Analysts anticipate these programs will advance to Phase III, backed by a strong cash runway extending into 2028. The company's valuation is currently below its potential, suggesting significant upside if clinical outcomes prove successful and address key market needs.
We Think ORIC Pharmaceuticals (NASDAQ:ORIC) Can Afford To Drive Business Growth
This article analyzes ORIC Pharmaceuticals' financial position, concluding that the company has sufficient cash reserves to fund its growth initiatives. It highlights the company's strong balance sheet and cash runway.
Blue Owl Capital Holdings LP Invests $4.33 Million in Oric Pharmaceuticals, Inc. $ORIC
Blue Owl Capital Holdings LP has invested $4.33 million in Oric Pharmaceuticals, Inc. (NASDAQ:ORIC), acquiring 400,000 shares, which represents 0.39% of ORIC and 0.7% of Blue Owl's portfolio. Institutional ownership of Oric Pharmaceuticals is high at 95.05%, with major firms like BlackRock and Vanguard increasing their stakes. Despite a recent stock dip and an EPS miss, analysts generally maintain a "Moderate Buy" rating with an average price target of $19.45.
HC Wainwright Issues Pessimistic Outlook for ORIC Earnings
HC Wainwright has revised down its earnings per share forecasts for Oric Pharmaceuticals (NASDAQ:ORIC) for Q3 2026 and FY2026, projecting larger losses. Despite the more pessimistic outlook, HC Wainwright maintained a "Buy" rating and a $27 price target on the stock. Oric Pharmaceuticals recently missed its Q2 earnings consensus, reporting a loss of $0.38 per share against an estimate of $0.36.
Understanding Momentum Shifts in (ORIC)
This article provides an analysis of Oric Pharmaceuticals Inc. (NASDAQ: ORIC), focusing on momentum shifts and potential trading strategies based on AI models. It highlights strong near and mid-term sentiment, identifies compelling upside potential due to the absence of resistance levels, and offers specific position, momentum breakout, and risk hedging trading strategies. The analysis also includes multi-timeframe signal analysis indicating support and resistance levels.
ORIC PHARMACEUTICALS, INC. : H.C. WAINWRIGHT RAISES TARGET PRICE TO $27 FROM $25
H.C. Wainwright has raised its target price for ORIC Pharmaceuticals, Inc. from $25 to $27. This adjustment suggests a positive outlook from the analytical firm regarding the company's future performance. The news was reported by Reuters.
ORIC Pharmaceuticals, Inc. (ORIC) options chain
This article provides the options chain for ORIC Pharmaceuticals, Inc. (ORIC), including call and put options with various strike prices and expiration dates. It details last trade dates, prices, bids, asks, volume, open interest, and implied volatility for contracts expiring on February 19, 2027. The current stock price of ORIC is reported as $13.96, up 1.68%.
Price to book forward of Oric Pharmaceuticals, Inc. – HAM:4TZ
The article displays the "Price to book forward" for Oric Pharmaceuticals, Inc. (HAM:4TZ) on the Hamburg Stock Exchange. It indicates that the market was closed with no trades recorded for the period. The content provides a snapshot of financial data related to this specific company.
ORIC PHARMACEUTICALS, INC. : H.C. WAINWRIGHT RAISES TARGET PRICE TO $27 FROM $25
H.C. Wainwright has increased its target price for ORIC PHARMACEUTICALS, INC. (ORIC.O) from $25 to $27. This update was reported by Reuters and indicates a positive adjustment in the analyst's valuation of the pharmaceutical company.
ORIC Pharmaceuticals (ORIC) Q2 Losses Put Valuation In Focus As Shares Rally
ORIC Pharmaceuticals (ORIC) has garnered attention after reporting Q2 2026 results, showing wider net losses but improved basic loss per share, alongside significant share price momentum. The company's price-to-book ratio of 3.7x is below its direct peer average but above the broader US Biotechs industry average, indicating mixed market valuation signals. Despite being unprofitable and forecasting continued losses, the current valuation reflects expectations stronger than the sector but more cautious than its direct peer group.
H.C. Wainwright raises ORIC Pharmaceuticals price target to $27 on pipeline progress
H.C. Wainwright increased its price target for ORIC Pharmaceuticals (NASDAQ:ORIC) to $27 from $25, maintaining a Buy rating, citing a catalyst-rich second half of 2026 for the biopharmaceutical company. ORIC is expected to provide updates on its ORIC-944 program and present new data for enozertinib in various non-small cell lung cancer treatments. This positive outlook follows other analyst coverage and a recent upgrade from Goldman Sachs, highlighting ORIC's progress in its pipeline, particularly with its lead asset, rinzimetostat.
Oric Pharmaceuticals, Inc. (NASDAQ:ORIC) Receives Average Recommendation of "Moderate Buy" from Brokerages
Oric Pharmaceuticals, Inc. (NASDAQ:ORIC) has received a "Moderate Buy" consensus recommendation from sixteen brokerages, with an average 12-month price target of $19.27. Despite missing its last quarterly earnings estimate, institutional investors hold a significant portion of ORIC shares, and several research firms have recently updated their ratings, mostly positively. The company, a clinical-stage biopharmaceutical firm, focuses on developing small molecule therapeutics for solid tumor oncology.
ORIC Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
ORIC Pharmaceuticals, Inc. (NASDAQ: ORIC) announced inducement grants to two new employees. These grants include non-statutory stock options to purchase 32,500 shares of common stock and restricted stock units (RSUs) representing the right to receive 15,000 shares of common stock. The grants were made as an inducement material to the employees entering employment with ORIC, in compliance with Nasdaq Listing Rule 5635(c)(4).
Dimensional Fund Advisors LP Boosts Holdings in Oric Pharmaceuticals, Inc. $ORIC
Dimensional Fund Advisors LP significantly increased its stake in Oric Pharmaceuticals (NASDAQ:ORIC) by 19.9% in the first quarter, bringing its total holdings to 1.47 million shares valued at $18.6 million. Institutional investors now collectively own 95.05% of the company. Despite the positive institutional interest and a "Moderate Buy" average analyst rating with a target price of $19.27, Oric Pharmaceuticals reported a quarterly loss of $0.38 per share, missing consensus estimates, and analysts anticipate a full-year loss of $1.49 per share.
Price to book forward of Oric Pharmaceuticals, Inc. – SWB:4TZ
This article provides a financial snapshot for Oric Pharmaceuticals, Inc. (SWB:4TZ) on the Stuttgart Stock Exchange. It specifically highlights the "Price to book forward" metric. The article is brief and presents no specific financial values but confirms the market is closed with no trades.
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
ORIC Pharmaceuticals announced inducement grants of non-qualified stock options and restricted stock units to five new non-executive employees, effective August 3, 2026. These grants, totaling 125,400 stock options and 20,550 restricted stock units, were approved by the Compensation Committee of the Board of Directors under Nasdaq Rule 5635(c)(4) as a material inducement to employment. The vesting schedules for these grants are detailed, with stock options vesting over four years and restricted stock units over three years.
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
ORIC Pharmaceuticals announced inducement grants to five new non-executive employees, including 125,400 non-qualified stock options and 20,550 restricted stock units. These grants, approved by ORIC's Compensation Committee, were made on August 3, 2026, as a material inducement to employment in accordance with Nasdaq Rule 5635(c)(4). The company specializes in developing treatments to overcome therapeutic resistance in cancer, with product candidates like rinzimetostat and enozertinib.
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
ORIC Pharmaceuticals announced inducement grants to five new non-executive employees, consisting of 125,400 non-qualified stock options and 20,550 restricted stock units. These grants, approved by ORIC's Compensation Committee, were made on August 3, 2026, as a material inducement for employment and are subject to specific vesting schedules. The company also provided an overview of its clinical-stage oncology product candidates.
Do ORIC Pharmaceuticals’ Widening Losses But Lower Per-Share Losses Reveal a Strategic Trade-Off for ORIC?
ORIC Pharmaceuticals reported widening net losses but improving per-share losses in the second quarter and first half of 2026, primarily due to a larger share count. The company remains a high-risk biotech story, relying on its oncology pipeline and continued equity financing, with future clinical trial results acting as key catalysts. Investors face potential dilution risks and a wide range of fair value estimates, highlighting the speculative nature of the investment.
Evercore ISI Keeps Their Buy Rating on Oric Pharmaceuticals (ORIC)
Evercore ISI analyst Cory Kasimov has maintained a Buy rating on Oric Pharmaceuticals (ORIC) with a price target of $25.00. Kasimov has a strong track record in the Healthcare sector, and Oric Pharmaceuticals holds a consensus "Strong Buy" rating from analysts. The company recently reported a quarterly GAAP net loss of $41.49 million for the quarter ending June 30.
Do ORIC Pharmaceuticals’ Widening Losses But Lower Per-Share Losses Reveal a Strategic Trade-Off for ORIC?
ORIC Pharmaceuticals reported widening net losses in Q2 and the first half of 2026, reaching US$41.49 million and US$77.26 million respectively. Despite this, the company saw improved basic and diluted loss per share due to a larger share count. The article suggests that equity remains the primary funding mechanism for the high-risk biotech firm, with clinical trial execution being the near-term catalyst.
Do ORIC Pharmaceuticals’ Widening Losses But Lower Per-Share Losses Reveal a Strategic Trade-Off for ORIC?
ORIC Pharmaceuticals reported widening net losses for Q2 and H1 2026, reaching US$41.49 million and US$77.26 million respectively. Despite this, basic and diluted loss per share improved to US$0.38 and US$0.72 for the same periods, primarily due to a larger share count. The company's investment narrative remains that of a high-risk biotech heavily reliant on its oncology pipeline, with future dilution and clinical trial success being key factors for investors.
Oric Pharmaceuticals (NASDAQ:ORIC) Trading 12.3% Higher - Here's What Happened
Oric Pharmaceuticals (NASDAQ:ORIC) saw its shares rise by 12.3% in midday trading on Tuesday, despite a significant drop in trading volume and a recent earnings miss. The company maintains a "Moderate Buy" consensus rating from analysts, with a target price of $19.27, and institutional investors hold a substantial 95.05% of its stock.
Stock Traders Purchase High Volume of Put Options on Oric Pharmaceuticals (NASDAQ:ORIC)
Traders purchased a significantly high volume of put options on Oric Pharmaceuticals (NASDAQ:ORIC), indicating bearish sentiment or a desire for downside protection. This activity occurred despite the company's shares rising and analysts maintaining a "Moderate Buy" consensus rating with an average target price of $19.27. Institutional investors hold a substantial portion of the company's stock.
ORIC Starts Global Prostate Cancer Trial Expected to Enroll About 600
ORIC Pharmaceuticals reported its Q2 2026 financial results, highlighting the initiation of the global Phase 3 Himalayas-1 trial for rinzimetostat in metastatic castration-resistant prostate cancer (mCRPC), which is expected to enroll approximately 600 patients. The company also announced a collaboration with Bayer for the trial and stated that its cash and investments of $387.6 million are expected to fund operations into the second half of 2028. Despite a net loss of $41.5 million in Q2, ORIC emphasized its advancement into a diversified, late-stage oncology company.
